These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 24751502

  • 1. Enhancement of myocardial function and reduction of injury with levosimendan after percutaneous coronary intervention for acute myocardial infarction: a pilot study.
    Wu X, Wu J, Yan X, Zhang Y.
    Cardiology; 2014; 128(2):202-8. PubMed ID: 24751502
    [Abstract] [Full Text] [Related]

  • 2. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction.
    De Luca L, Proietti P, Celotto A, Bucciarelli-Ducci C, Benedetti G, Di Roma A, Sardella G, Genuini I, Fedele F.
    Am Heart J; 2005 Sep; 150(3):563-8. PubMed ID: 16169341
    [Abstract] [Full Text] [Related]

  • 3. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia.
    Sonntag S, Sundberg S, Lehtonen LA, Kleber FX.
    J Am Coll Cardiol; 2004 Jun 16; 43(12):2177-82. PubMed ID: 15193677
    [Abstract] [Full Text] [Related]

  • 4. Facilitation of left ventricular function recovery post percutaneous coronary intervention by levosimendan.
    Qarawani D, Cohen A, Nahir M, Hasin Y.
    Int J Cardiol; 2013 Sep 20; 168(1):237-42. PubMed ID: 23063476
    [Abstract] [Full Text] [Related]

  • 5. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
    Husebye T, Eritsland J, Müller C, Sandvik L, Arnesen H, Seljeflot I, Mangschau A, Bjørnerheim R, Andersen GØ.
    Eur J Heart Fail; 2013 May 20; 15(5):565-72. PubMed ID: 23288914
    [Abstract] [Full Text] [Related]

  • 6. Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction.
    Christoph A, Prondzinsky R, Russ M, Janusch M, Schlitt A, Lemm H, Reith S, Werdan K, Buerke M.
    Acute Card Care; 2008 May 20; 10(1):49-57. PubMed ID: 17924229
    [Abstract] [Full Text] [Related]

  • 7. Milrinone and levosimendan administered after reperfusion improve myocardial stunning in swine.
    Shibata I, Cho S, Yoshitomi O, Ureshino H, Maekawa T, Hara T, Sumikawa K.
    Scand Cardiovasc J Suppl; 2013 Feb 20; 47(1):50-7. PubMed ID: 22994851
    [Abstract] [Full Text] [Related]

  • 8. Levosimendan cardioprotection reduces the metabolic response during temporary regional coronary occlusion in an open chest pig model.
    Metzsch C, Liao Q, Steen S, Algotsson L.
    Acta Anaesthesiol Scand; 2007 Jan 20; 51(1):86-93. PubMed ID: 17073861
    [Abstract] [Full Text] [Related]

  • 9. Early 'in-lab' use of levosimendan in patients with cardiogenic shock unsuitable for intra-aortic balloon pump counterpulsation.
    Summaria F, Mustilli M, Sette A, Lanzillo C, Romagnoli E.
    Ther Adv Cardiovasc Dis; 2014 Feb 20; 8(1):28-31. PubMed ID: 24492986
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction.
    Jia Z, Guo M, Zhang YQ, Liang HQ, Zhang LY, Song Y.
    Cardiology; 2014 Feb 20; 128(2):195-201. PubMed ID: 24751462
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial.
    Lincoff AM, Roe M, Aylward P, Galla J, Rynkiewicz A, Guetta V, Zelizko M, Kleiman N, White H, McErlean E, Erlinge D, Laine M, Dos Santos Ferreira JM, Goodman S, Mehta S, Atar D, Suryapranata H, Jensen SE, Forster T, Fernandez-Ortiz A, Schoors D, Radke P, Belli G, Brennan D, Bell G, Krucoff M, PROTECTION AMI Investigators.
    Eur Heart J; 2014 Oct 01; 35(37):2516-23. PubMed ID: 24796339
    [Abstract] [Full Text] [Related]

  • 12. Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial.
    Post S, Post MC, van den Branden BJ, Eefting FD, Goumans MJ, Stella PR, van Es HW, Wildbergh TX, Rensing BJ, Doevendans PA.
    Catheter Cardiovasc Interv; 2012 Nov 01; 80(5):756-65. PubMed ID: 22419603
    [Abstract] [Full Text] [Related]

  • 13. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
    Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS.
    Arterioscler Thromb Vasc Biol; 2013 Sep 01; 33(9):2252-60. PubMed ID: 23868944
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study.
    Anastasiadis K, Antonitsis P, Vranis K, Kleontas A, Asteriou C, Grosomanidis V, Tossios P, Argiriadou H.
    Interact Cardiovasc Thorac Surg; 2016 Nov 01; 23(5):740-747. PubMed ID: 27378790
    [Abstract] [Full Text] [Related]

  • 15. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study.
    De Luca L, Sardella G, Proietti P, Battagliese A, Benedetti G, Di Roma A, Fedele F.
    J Am Soc Echocardiogr; 2006 Feb 01; 19(2):172-7. PubMed ID: 16455421
    [Abstract] [Full Text] [Related]

  • 16. Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.
    Lechner E, Moosbauer W, Pinter M, Mair R, Tulzer G.
    Pediatr Crit Care Med; 2007 Jan 01; 8(1):61-3. PubMed ID: 17149153
    [Abstract] [Full Text] [Related]

  • 17. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
    Meyer K, Klocke RC, Schipke JD, Gams E, Korbmacher B.
    Eur J Cardiothorac Surg; 2008 Aug 01; 34(2):326-31. PubMed ID: 18539040
    [Abstract] [Full Text] [Related]

  • 18. Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan.
    Russ MA, Prondzinsky R, Carter JM, Schlitt A, Ebelt H, Schmidt H, Lemm H, Heinroth K, Soeffker G, Winkler M, Werdan K, Buerke M.
    Crit Care Med; 2009 Dec 01; 37(12):3017-23. PubMed ID: 19661807
    [Abstract] [Full Text] [Related]

  • 19. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
    Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W.
    Circulation; 2000 Oct 31; 102(18):2222-7. PubMed ID: 11056096
    [Abstract] [Full Text] [Related]

  • 20. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.
    Am J Cardiol; 2006 Jul 01; 98(1):102-6. PubMed ID: 16784930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.